CN100549011C - 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 - Google Patents

用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 Download PDF

Info

Publication number
CN100549011C
CN100549011C CNB038250470A CN03825047A CN100549011C CN 100549011 C CN100549011 C CN 100549011C CN B038250470 A CNB038250470 A CN B038250470A CN 03825047 A CN03825047 A CN 03825047A CN 100549011 C CN100549011 C CN 100549011C
Authority
CN
China
Prior art keywords
alkyl
compound
aryl
unsubstituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038250470A
Other languages
English (en)
Chinese (zh)
Other versions
CN1703414A (zh
Inventor
M·P·德怀尔
T·J·古兹
K·帕鲁奇
R·J·多尔
K·M·基尔蒂卡
V·M·吉里亚瓦拉布汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1703414A publication Critical patent/CN1703414A/zh
Application granted granted Critical
Publication of CN100549011C publication Critical patent/CN100549011C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038250470A 2002-09-19 2003-09-17 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 Expired - Fee Related CN100549011C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41206302P 2002-09-19 2002-09-19
US60/412,063 2002-09-19

Publications (2)

Publication Number Publication Date
CN1703414A CN1703414A (zh) 2005-11-30
CN100549011C true CN100549011C (zh) 2009-10-14

Family

ID=32030794

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038250470A Expired - Fee Related CN100549011C (zh) 2002-09-19 2003-09-17 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶

Country Status (18)

Country Link
US (2) US6992080B2 (https=)
EP (1) EP1539756B1 (https=)
JP (1) JP4845379B2 (https=)
KR (1) KR20050052500A (https=)
CN (1) CN100549011C (https=)
AR (1) AR041291A1 (https=)
AT (1) ATE378336T1 (https=)
AU (1) AU2003295332B2 (https=)
CA (1) CA2499639C (https=)
DE (1) DE60317529T2 (https=)
ES (1) ES2293068T3 (https=)
IL (1) IL167433A (https=)
MX (1) MXPA05003058A (https=)
MY (1) MY133311A (https=)
NZ (1) NZ538566A (https=)
TW (1) TWI351405B (https=)
WO (1) WO2004026867A2 (https=)
ZA (1) ZA200502278B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
GB9819530D0 (en) 1998-09-09 1998-10-28 Smithkline Beecham Plc Novel compositions and use
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
KR20070107707A (ko) * 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
PE20061110A1 (es) * 2005-03-24 2006-10-20 Glaxo Group Ltd Derivados de imidazopiridina como antagonistas de la bomba de acido (apa)
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
JP2010511019A (ja) * 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CA2708361C (en) * 2007-12-14 2016-06-07 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
AU2008343065B2 (en) * 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
JPWO2010035745A1 (ja) * 2008-09-25 2012-02-23 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EA021293B1 (ru) 2008-12-08 2015-05-29 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102307474B (zh) 2008-12-08 2015-04-01 吉利德康涅狄格股份有限公司 咪唑并吡嗪syk抑制剂
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN103168039B (zh) 2010-03-11 2016-08-03 吉利德康涅狄格公司 咪唑并吡啶类syk抑制剂
ES2545135T3 (es) * 2011-04-06 2015-09-08 Bayer Pharma Aktiengesellschaft Imidazopiridinas sustituidas y compuestos intermedios de las mismas
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
HK1206250A1 (en) 2012-06-26 2016-01-08 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2919522C (en) 2013-07-30 2019-02-26 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
CN105764516A (zh) 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
EP3402798B1 (en) 2016-01-14 2021-04-28 Handok Inc. Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof
US11161843B2 (en) 2017-01-24 2021-11-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
MX392743B (es) * 2017-04-12 2025-03-12 Magenta Therapeutics Inc Antagonistas del receptor de hidrocarburo de arilo y sus usos.
WO2018195397A2 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
PT4065582T (pt) 2019-11-26 2025-05-22 Ikena Oncology Inc Derivados polimórficos do carbazol e utilizações dos mesmos
WO2024068740A1 (en) * 2022-09-28 2024-04-04 Origenis Gmbh Novel cdk9 inhibitors
WO2025058459A1 (ko) * 2023-09-15 2025-03-20 (주)휴온스 신규한 이미다조피리딘계 화합물 및 이를 유효성분으로 포함하는 위장관 염증질환 또는 위산-관련 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
WO1995007276A1 (en) * 1993-09-10 1995-03-16 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
JP4007743B2 (ja) * 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
WO2001056607A1 (en) 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
SE0003186D0 (sv) 2000-09-07 2000-09-07 Astrazeneca Ab New process
EP1370261A2 (en) * 2001-03-08 2003-12-17 AstraZeneca AB New use

Also Published As

Publication number Publication date
AU2003295332B2 (en) 2007-01-18
NZ538566A (en) 2008-02-29
AU2003295332A1 (en) 2004-04-08
EP1539756B1 (en) 2007-11-14
WO2004026867A2 (en) 2004-04-01
CN1703414A (zh) 2005-11-30
MY133311A (en) 2007-11-30
DE60317529T2 (de) 2008-09-25
DE60317529D1 (de) 2007-12-27
AR041291A1 (es) 2005-05-11
CA2499639C (en) 2011-11-08
JP2006507254A (ja) 2006-03-02
ATE378336T1 (de) 2007-11-15
US6992080B2 (en) 2006-01-31
IL167433A (en) 2011-03-31
WO2004026867A3 (en) 2004-08-05
JP4845379B2 (ja) 2011-12-28
KR20050052500A (ko) 2005-06-02
HK1071757A1 (en) 2005-07-29
ZA200502278B (en) 2006-05-31
US7452902B2 (en) 2008-11-18
CA2499639A1 (en) 2004-04-01
EP1539756A2 (en) 2005-06-15
US20060030555A1 (en) 2006-02-09
US20040097517A1 (en) 2004-05-20
TW200407322A (en) 2004-05-16
ES2293068T3 (es) 2008-03-16
MXPA05003058A (es) 2005-05-27
TWI351405B (en) 2011-11-01

Similar Documents

Publication Publication Date Title
CN100549011C (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
JP4799864B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
CN1701073B (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
JP5109109B2 (ja) サイクリン依存性キナーゼ阻害剤としての新規イミダゾピラジン
JP4571969B2 (ja) キナーゼインヒビターとしてのピラゾロトリアジン
JP2006503838A (ja) サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
JP2006502184A5 (https=)
US7700773B2 (en) 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
JP2010168406A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
CN101541804A (zh) 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
JP2009511477A (ja) サイクリン依存性キナーゼインヒビターとしての、新規なピラゾロピリミジン
CN100475812C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091014

Termination date: 20120917